ZacksResearch
Sep 28, 2:09 PM
🚀
$QNTM just cleared a major hurdle for Lucid-MS
Quantum BioPharma received FDA approval of its IND application for Lucid-MS, clearing the way for the company's lead multiple sclerosis candidate to advance into Phase 2 testing.
Key takeaways:
• FDA IND approval allows Quantum BioPharma to move Lucid-MS into Phase 2 clinical testing
• The candidate previously completed Phase 1, where it showed a favorable safety profile and was well tolerated
• Quantum says Lucid-MS uses a different mechanism from most existing MS therapies
• The next step is to begin patient recruitment and Phase 2 clinical testing
• The milestone moves Lucid-MS from early-stage development toward testing for potential therapeutic benefit in MS
Price target breakdown here 👇
https://www.zacks.com/stock/research/QNTM/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-39726&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_39726
